Pluri vs ProKidney
PLUR and PROK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PLUR and PROK compare
ProKidney is the larger company, worth 24 times as much as Pluri ($316M against $13.0M).
Pluri grew revenue faster over the last twelve months (10.0% versus 4.2% for ProKidney).
Pluri keeps more of each dollar of sales as profit, with a net margin of −1944% compared with −13327% at ProKidney.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PLUR | PROK |
|---|---|---|
| Size and price | ||
| Market cap | $13.0M | $316M |
| Share price | $1.05 | $1.04 |
| Change, 1 year | −76.4% | −61.0% |
| Change, 5 years | −95.0% | −89.5% |
| Beta (5Y) | 0.95 | 1.30 |
| Employees | 92 | 231 |
| StockData Score | ||
| Total score | 4 | 4 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.9× (better) | 408× |
| FCF yield | −148% | −53.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.0% (better) | 4.2% |
| Profitability | ||
| Gross margin | 52.0% | – |
| Operating margin | −2341% (better) | −24830% |
| Net margin | −1944% (better) | −13327% |
| FCF margin | −1318% (better) | −21655% |
| Financial health | ||
| Interest coverage | −36.8× (better) | −10690.8× |
| Current ratio | 0.27 | 5.04 (better) |
| Altman Z-score | −32.23 | −5.65 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −5.4% |
| Shareholder yield | 0.00% (better) | −5.4% |
| Ownership | ||
| Held by institutions | 0.22% | 16.1% |
| Held by insiders | 54.6% | 62.9% |
| Insider net buying, 12 months | $1.3M (better) | −$1.1M |
| Short interest, % of float | 1.4% | 21.7% |
Go deeper
- PLUR stock overview
- PLUR income statement
- PLUR valuation and score
- PROK stock overview
- PROK income statement
- PROK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.